Akari Therapeutics and Whitehawk Expand Dual-Payload ADC Strategy
Tampa, Florida and London, United Kingdom — August 13, 2026 Akari Therapeutics, Plc reported progress on its lead antibody-drug...
cancer therapy
Advertisement
Propanc Biopharma Advances PRP as a Novel Approach for RAS-Driven Cancers
MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...
BioInvent Receives FDA Fast Track Designation for BI-1808
LUND, Sweden, August 7, 2026 BioInvent International AB announced that the U.S. Food and Drug Administration (FDA) has granted...
Replimune’s RP1 Gains FDA Panel Support for Advanced Melanoma
WOBURN, Mass., July 30, 2026 Replimune Group, Inc. announced a favorable outcome from the U.S. Food and Drug Administration’s...
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
Advertisements
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Corbus Moves CRB-701 Toward FDA Registration
NORWOOD, Mass., July 28, 2026 Corbus Pharmaceuticals Holdings, Inc. has received U.S. Food and Drug Administration (FDA) clearance to...
Firefly Bio Acquisition Strengthens J&J Cancer Portfolio
MONTEREY, Calif., July 29, 2026 Johnson & Johnson has completed its $1 billion acquisition of Firefly Bio, Inc., significantly...
Calidi Biotherapeutics Highlights CLD-401 Cancer Therapy Data
SAN DIEGO, July 27, 2026 Calidi Biotherapeutics presented new preclinical data from its CLD-401 program and its in situ...
Advertisement
